Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents

Lignende værker

• Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations
  af: Benton, Chris, et al.
  Udgivet: (2013)
• Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
  af: DiNardo, Courtney D., et al.
  Udgivet: (2015)
• Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients With AML Treated With High Dose Cytarabine and Idarubicin
  af: Ravandi, Farhad, et al.
  Udgivet: (2011)
• Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients
  af: Takahashi, Koichi, et al.
  Udgivet: (2015)
• Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
  af: Musa Yilmaz, et al.
  Udgivet: (2022-05-01)